Tirzepatide / Niacinamide Injection
US$ 24.82
![surmount-1 trial tirzepatide obesity without diabetes In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide as Anti-Obesity Agent](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
surmount-1 trial tirzepatide obesity without diabetes In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide as Anti-Obesity Agent
Description
Inadequate response to Wegovy
![surmount-1 trial tirzepatide obesity without diabetes In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide as Anti-Obesity Agent](https://lupinepublishers.com/diabetes-obesity-journal/table/lupinepublishers-openaccess-journal-diabetes-obesity.ID.000183.T001.png)
What the clinical trials tell us indirectly The SURMOUNT clinical trial program provides indirect evidence that lower doses can be effective
![surmount-1 trial tirzepatide obesity without diabetes In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide as Anti-Obesity Agent](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=122136430784067432)
Stay on track with your routine
![surmount-1 trial tirzepatide obesity without diabetes In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide as Anti-Obesity Agent](https://dom-pubs.onlinelibrary.wiley.com/cms/asset/255fe113-017e-4c28-816f-13c8c2e8641f/dom16176-fig-0004-m.jpg)
Why Tirzepatide Might Make You Feel Cold Tirzepatide reduces appetite by activating GLP-1 and GIP pathways in your brain and digestive system
![surmount-1 trial tirzepatide obesity without diabetes In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide as Anti-Obesity Agent](https://www.mayoclinicproceedings.org/cms/10.1016/j.mayocp.2024.07.006/asset/e9fbe822-a25e-4f03-8fe7-5b231ff8e173/main.assets/ga1_lrg.jpg)
32 Both in terms of observational data and neurological plausibility, tirzepatide and semaglutide appear to be promising for reducing cravings, moderating use of various substances, and treating or preventing addictions
![surmount-1 trial tirzepatide obesity without diabetes In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide as Anti-Obesity Agent](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13300-025-01723-w/MediaObjects/13300_2025_1723_Fig2_HTML.png)
Units measure volume on the syringe
![surmount-1 trial tirzepatide obesity without diabetes In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide as Anti-Obesity Agent](https://www.truveta.com/wp-content/uploads/2024/12/GLP-1-study-validated.png)